1. Scrip
  2. >>Advanced Therapies

Vertex Ends One Type 1 Diabetes Cell Therapy, Shifts Focus To Another

 
• By Joseph Haas

Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.

Embryonic stem cells , Cellular therapy , Regeneration , Disease treatment , 3d illustration - Illustration
Vertex continues its stem cell-based approach to type 1 diabetes

Vertex remains bullish on prospects for developing curative, endogenous insulin-sparing cell therapies for type 1 diabetes, despite disappointing results unveiled on 28 March that led the Boston-based firm to end development of VX-264, an encapsulated formulation of pancreatic islet stem cells designed to avoid detection by a patient’s immune system.

Key Takeaways
  • Vertex will end development of its encapsulated cell therapy VX-264 for type 1 diabetes, but expects to file for approval of a different cell therapy,...

The company revealed that findings from a Phase I/II study of VX-264 showed good safety, but did not demonstrate enough efficacy in terms of increasing production of C-peptide, a key...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cell Therapies

More from Therapy Areas

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Merck KGaA Plans Phase III For Enpatoran After Mixed Phase II Lupus Data

 
• By Jessica Merrill

The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.

PureTech’s IPF Candidate Ready For Phase III After Efficacy Win

 
• By Andrew McConaghie

Coming one day after Boehringer’s underwhelming data, PureTech’s tweaked molecule, deupirfenidone, shows promise in slowing idiopathic pulmonary fibrosis.